- Bristol-Myers Squibb (BMY, Financial) stands out with a robust drug pipeline and consistent dividends, appealing to value-seeking income investors.
- Analysts suggest an average potential upside of 16.67% based on current price targets.
- GuruFocus estimates indicate a potential 31.63% increase in GF Value within a year.
Bristol-Myers Squibb (BMY) is solidifying its leadership in the pharmaceutical industry through a compelling growth strategy underscored by a pipeline of innovative drugs. With a remarkable track record of dividend increases spanning 16 years and a forward P/E ratio of 7.24, BMY continues to offer a compelling opportunity for income investors who prioritize value and stability.
Wall Street Analysts Forecast
According to projections from 21 seasoned analysts, the one-year average price target for Bristol-Myers Squibb Co (BMY, Financial) stands at $55.88. Price estimates range from a high of $68.00 to a low of $33.10. This average target price suggests an attractive upside of 16.67% from the current trading price of $47.90. Investors can delve into more detailed estimate data on the Bristol-Myers Squibb Co (BMY) Forecast page.
The consensus recommendation from 28 brokerage firms designates a "Hold" status for Bristol-Myers Squibb Co (BMY, Financial), with an average brokerage recommendation of 2.7. This rating is based on a scale ranging from 1 to 5, where 1 represents a Strong Buy and 5 signifies a Sell.
GuruFocus Valuation
Leveraging proprietary metrics, GuruFocus estimates the GF Value for Bristol-Myers Squibb Co (BMY, Financial) to reach $63.05 within the next year. This indicates a potential upside of 31.63% from the current price of $47.90. The GF Value is derived from historical trading multiples, prior business growth, and forecasts of future performance. Investors can access more comprehensive data on the Bristol-Myers Squibb Co (BMY) Summary page.
Also check out: (Free Trial)
